Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-30
Abstract Views: 128
Views PDF (Tiếng Việt): 137
DOI: https://doi.org/10.52852/tcncyh.v160i12V2.1310
Issue
Vol. 160 No. 12V2 (2022)
Section
Các bài báo
How to Cite
Mậu, N. T. T. ., Khánh, T. V. ., Toàn, N. L. ., Tuấn, N. Đức ., Bình, N. T. ., & Thịnh, T. H. . (2023). 24. Anti-cancer effect of gamma delta T cells in an immunodeficient mouse model bearing human lung cancer. Journal of Medical Research, 160(12V2), 198-205. https://doi.org/10.52852/tcncyh.v160i12V2.1310

24. Anti-cancer effect of gamma delta T cells in an immunodeficient mouse model bearing human lung cancer

Nguyen Thi Thuy Mau, Tran Van Khanh, Nguyen Linh Toan, Nguyen Duc Tuan, Nguyen Thanh Binh, Tran Huy Thinh

Main Article Content

Abstract

This study aims to evaluate the anti-cancer effect of gamma delta T (γδT) cells in an immunodeficient mouse model bearing human lung cancer (H460 lineage). Gamma delta T (γδT) cells were activated and proliferated in vitro until a concentration of at least 107 cells/ml was reached. Immune-deficient mice bearing human lung cancer were divided into 4 groups with 6 animals per group, including 1 control group and 3 treatment groups (GDT1, GDT2, GDT3). The three treatment groups were injected with 106 cells/10g, 5x106 cells/10g, and 107 cells/10g concentrations of γδT cells. After injection, at day 20, the GDT3 group with H460 human lung cancer had a smaller tumor volume, longer survival time, and lower death rate compared to the control group. The results suggest that γδT cells may be effective against human lung cancer in an immune-deficient mouse model of xenograft tumors.

Article Details

Keywords

gama delta T cells, lung cancer, immunodeficient Mouse

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.
2. WHO. International Agency for Research on Cancer. Globocan 2020. Accessed October 19, 2022. https://gco.iarc.fr/today/data/fact sheets/populations/704-viet-nam-fact-sheets.pdf.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013.
4. Tartour E, Zitvogel L. Lung cancer: Potential targets for immunotherapy. Lancet Respir Med. 2013;1(7):551-563. doi: 10.1016/S2213-2600(13)70159-0.
5. Bonneville M, O’Brien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10(7):467-478. doi: 10.1038/nri2781.
6. Xu Y, Xiang Z, Alnaggar M, et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18(2):427-439. doi: 10.1038/s41423-020-0515-7.
7. Wu YL, Ding YP, Tanaka Y, et al. γδ T cells and their potential for immunotherapy. Int J Biol Sci. 2014;10(2):119-135. doi: 10.7150/ijbs.7823.
8. Lo Presti E, Pizzolato G, Gulotta E, et al. Current Advances in γδ T Cell-Based Tumor Immunotherapy. Frontiers in Immunology. 2017;8. Accessed October 22, 2022. https://www.frontiersin.org/articles/10.3389/fimmu.2017.01401.
9. Beck BH, Kim HG, Kim H, et al. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Treat. 2010;122(1):135-144. doi: 10.1007/s10549-009-0527-6.
10. Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol. 2004;173(11):6767-6776. doi: 10.4049/jimmunol.173.11.6767.